Attempts to overcome TKI resistance focus on the development of next-generation EGFR-TKIs, which show therapeutic activity against reactivated EGFR-mutated lung cancers; however, treatment results in the acquisition of further resistance through additional EGFR mutations, as well as the activation of EGFR-independent bypass signaling [21]. Here, EGFR is linked to lung carcinoma.